Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Cybin announces FDA authorization of IND for Kernal's Flow study of ketamine » 07:38
10/26/21
10/26
07:38
10/26/21
07:38
CYBN

Cybin

$2.00 /

+0.06 (+3.09%)

Cybin announced that the…

Cybin announced that the U.S. Food and Drug Administration has authorized an Investigational New Drug application to proceed with the Company's sponsored feasibility study using Kernel's Flow technology to measure ketamine's psychedelic effect on cerebral cortex hemodynamics. "The word psychedelic means 'mind-manifesting,' but what has been missing is useful 'mind-imaging'-the ability to dynamically trace the neural correlates of human conscious experience. Conventional neuroimaging just isn't dynamic enough to study the psychedelic experience in the brain as it happens. This study of ketamine's psychedelic effects while wearing headgear equipped with sensors to record brain activity could open up new frontiers of understanding," said Dr. Alex Belser, Cybin's Chief Clinical Officer. Leveraging Kernel's quantitative neuroimaging technology may lead to new frontiers in psychedelic therapeutics by enabling the acquisition of longitudinal brain activity before, during and after a psychedelic experience, providing quantification of what was previously subjective patient reporting. "Quantitatively measuring the brain within the context of a psychedelic experience is a promising frontier," said Bryan Johnson, founder and Chief Executive Officer of Kernel. "With Kernel Flow, Cybin's researchers can start putting numbers and quantification to subjective states of mind, including altered ones."

ShowHide Related Items >><<
CYBN Cybin
$2.00 /

+0.06 (+3.09%)

CYBN Cybin
$2.00 /

+0.06 (+3.09%)

10/04/21 Oppenheimer
Cybin initiated with an Outperform rating, $7 target at Oppenheimer
10/04/21 Oppenheimer
Cybin initiated with an Outperform at Oppenheimer
08/27/21 Canaccord
Cybin price target raised to $7 from $6 at Canaccord
08/26/21 Cantor Fitzgerald
Cybin initiated with an Overweight at Cantor Fitzgerald
CYBN Cybin
$2.00 /

+0.06 (+3.09%)

Over a week ago
Hot Stocks
Mindset expands benchmarking data for first generation psychedelices » 07:35
10/14/21
10/14
07:35
10/14/21
07:35
MSSTF

Mindset

/

+

Mindset Pharma announced…

Mindset Pharma announced that, under its Co-operative Psychedelics Evaluation Platform program with InterVivo Solutions, the Company has further developed its first generation psychedelics benchmarking data by establishing standard pharmacokinetic, brain penetration, and drug discrimination data and protocols across LSD, psilocybin, and 5-MeO-DMT. The COPE Program is a translational testing platform developed in cooperation with InterVivo to introduce an industry standard against which the performance and efficacy of breakthrough psychedelic medicines are compared and assessed. Through this platform, Mindset and InterVivo intend to establish the first comprehensive psychedelics benchmark reference data set by evaluating a broad range of psychedelic drugs through a proprietary program of in vivo tests conducted at InterVivo's facility. The COPE program is anticipated to represent an invaluable tool to guide the development of next-generation psychedelic compounds and improve patentability and value in new molecule drug assets.

ShowHide Related Items >><<
MSSTF Mindset
/

+

Conference/Events
OTC Markets Group to hold a virtual conference » 08:44
10/13/21
10/13
08:44
10/13/21
08:44
CYBN

Cybin

$2.05 /

-0.09 (-4.21%)

, ENVB

Enveric Biosciences

$1.98 /

+0.05 (+2.60%)

, FTRP

Field Trip Health

$4.74 /

-0.01 (-0.21%)

, HUGE

FSD Pharma

$1.49 /

+0.02 (+1.36%)

, MSSTF

Mindset

/

+

, TRYPF

Tryp Therapeutics

/

+

KCSA Psychedelics Virtual…

KCSA Psychedelics Virtual Conference to be held on October 13-14 beginning at 9:45 am. Webcast Link

ShowHide Related Items >><<
MSSTF Mindset
/

+

HUGE FSD Pharma
$1.49 /

+0.02 (+1.36%)

ENVB Enveric Biosciences
$1.98 /

+0.05 (+2.60%)

CYBN Cybin
$2.05 /

-0.09 (-4.21%)

CYBN Cybin
$2.05 /

-0.09 (-4.21%)

10/04/21 Oppenheimer
Cybin initiated with an Outperform rating, $7 target at Oppenheimer
10/04/21 Oppenheimer
Cybin initiated with an Outperform at Oppenheimer
08/27/21 Canaccord
Cybin price target raised to $7 from $6 at Canaccord
08/26/21 Cantor Fitzgerald
Cybin initiated with an Overweight at Cantor Fitzgerald
ENVB Enveric Biosciences
$1.98 /

+0.05 (+2.60%)

07/08/21 Aegis
Enveric Biosciences initiated with a Buy at Aegis
06/28/21 Maxim
Enveric Biosciences initiated with a Buy at Maxim
06/28/21 Maxim
Enveric Biosciences initiated with a Buy at Maxim
FTRP Field Trip Health
$4.74 /

-0.01 (-0.21%)

09/01/21 H.C. Wainwright
Field Trip Health initiated with a Buy at H.C. Wainwright
HUGE FSD Pharma
$1.49 /

+0.02 (+1.36%)

MSSTF Mindset
/

+

TRYPF Tryp Therapeutics
/

+

08/26/21 Ladenburg
Tryp Therapeutics initiated with a Buy at Ladenburg
HUGE FSD Pharma
$1.49 /

+0.02 (+1.36%)

CYBN Cybin
$2.05 /

-0.09 (-4.21%)

HUGE FSD Pharma
$1.49 /

+0.02 (+1.36%)

ENVB Enveric Biosciences
$1.98 /

+0.05 (+2.60%)

On The Fly
Fly Intel: After-Hours Movers » 18:44
10/04/21
10/04
18:44
10/04/21
18:44
NAPA

Duckhorn Portfolio

$23.50 /

+0.26 (+1.12%)

, TISI

Team

$3.24 /

+0.11 (+3.51%)

, IVAC

Intevac

$4.71 /

-0.04 (-0.84%)

, LULU

Lululemon

$392.49 /

-8.755 (-2.18%)

, CMTL

Comtech

$25.52 /

-0.65 (-2.48%)

, MGPI

MGP

$66.52 /

+0.37 (+0.56%)

, CYBR

CyberArk

$156.85 /

-2.66 (-1.67%)

, CYBN

Cybin

$2.10 /

-0.08 (-3.67%)

, RXDX

Prometheus

$23.15 /

+0.79 (+3.53%)

, RVLV

Revolve Group

$62.34 /

-1.125 (-1.77%)

, TDUP

ThredUP

$19.58 /

-1.01 (-4.91%)

, POSH

Poshmark

$23.58 /

-1.77 (-6.98%)

Check out this evening's…

ShowHide Related Items >><<
TISI Team
$3.24 /

+0.11 (+3.51%)

TDUP ThredUP
$19.58 /

-1.01 (-4.91%)

RXDX Prometheus
$23.15 /

+0.79 (+3.53%)

RVLV Revolve Group
$62.34 /

-1.125 (-1.77%)

POSH Poshmark
$23.58 /

-1.77 (-6.98%)

NAPA Duckhorn Portfolio
$23.50 /

+0.26 (+1.12%)

MGPI MGP
$66.52 /

+0.37 (+0.56%)

LULU Lululemon
$392.49 /

-8.755 (-2.18%)

IVAC Intevac
$4.71 /

-0.04 (-0.84%)

CYBN Cybin
$2.10 /

-0.08 (-3.67%)

CMTL Comtech
$25.52 /

-0.65 (-2.48%)

NAPA Duckhorn Portfolio
$23.50 /

+0.26 (+1.12%)

06/09/21 Citi
Duckhorn Portfolio price target raised to $25 from $22 at Citi
04/12/21
Fly Intel: Top five analyst initiations
04/12/21 Evercore ISI
Evercore ISI starts 'blue chip' Duckhorn at Outperform with $22 price target
04/12/21 Jefferies
Duckhorn Portfolio initiated with a Buy at Jefferies
TISI Team
$3.24 /

+0.11 (+3.51%)

03/12/21 KeyBanc
Team downgraded to Sector Weight from Overweight at KeyBanc
03/11/21 KeyBanc
Team downgraded to Sector Weight from Overweight at KeyBanc
IVAC Intevac
$4.71 /

-0.04 (-0.84%)

04/01/21 Northland
Microsoft award from Army could be positive catalyst for Intevac, says Northland
LULU Lululemon
$392.49 /

-8.755 (-2.18%)

09/17/21 Oppenheimer
Lululemon price target raised to $520 from $405 at Oppenheimer
09/10/21 Argus
Lululemon price target raised to $500 from $416 at Argus
09/10/21 UBS
Lululemon price target raised to $430 from $375 at UBS
09/09/21 Guggenheim
Lululemon price target raised to $475 from $450 at Guggenheim
CMTL Comtech
$25.52 /

-0.65 (-2.48%)

06/09/21 Northland
Comtech price target lowered to $28 from $31 at Northland
06/09/21 Citi
Comtech price target lowered to $26 from $29 at Citi
03/12/21 Northland
Comtech price target raised to $31 from $24 at Northland
12/17/20 Jefferies
Comtech upgraded to Buy from Hold at Jefferies
MGPI MGP
$66.52 /

+0.37 (+0.56%)

02/26/21
Fly Intel: Top five analyst downgrades
02/26/21 Truist
MGP downgraded to Hold from Buy at Truist
02/26/21 Truist
MGP downgraded to Hold from Buy at Truist
01/26/21 Craig-Hallum
MGP Ingredients price target raised to $55 from $42 at Craig-Hallum
CYBR CyberArk
$156.85 /

-2.66 (-1.67%)

10/04/21 Wells Fargo
CyberArk initiated with an Equal Weight at Wells Fargo
08/13/21 Wedbush
CyberArk price target raised to $160 from $150 at Wedbush
08/13/21 Baird
CyberArk price target raised to $170 from $160 at Baird
08/13/21 Stifel
CyberArk price target raised to $175 from $160 at Stifel
CYBN Cybin
$2.10 /

-0.08 (-3.67%)

10/04/21 Oppenheimer
Cybin initiated with an Outperform rating, $7 target at Oppenheimer
10/04/21 Oppenheimer
Cybin initiated with an Outperform at Oppenheimer
08/27/21 Canaccord
Cybin price target raised to $7 from $6 at Canaccord
08/26/21 Cantor Fitzgerald
Cybin initiated with an Overweight at Cantor Fitzgerald
RXDX Prometheus
$23.15 /

+0.79 (+3.53%)

10/04/21 Oppenheimer
Prometheus initiated with an Outperform at Oppenheimer
04/26/21 Credit Suisse
Prometheus assumed with an Outperform at Credit Suisse
04/06/21 SVB Leerink
SVB Leerink bullish on Prometheus, initiates with an Outperform
04/06/21 Stifel
Prometheus initiated with a Buy at Stifel
RVLV Revolve Group
$62.34 /

-1.125 (-1.77%)

10/04/21 Wedbush
Wedbush sees several key tailwinds for footwear and apparel sector
10/04/21 Wedbush
Revolve Group initiated with an Outperform at Wedbush
09/13/21 Jefferies
Revolve Group upgraded to Buy at Jefferies after management meetings
09/13/21 Jefferies
Revolve Group upgraded to Buy from Hold at Jefferies
TDUP ThredUP
$19.58 /

-1.01 (-4.91%)

10/04/21 Wedbush
ThredUP initiated with an Outperform at Wedbush
09/28/21 Berenberg
ThredUP initiated with a Hold at Berenberg
07/07/21 Needham
ThredUP initiated with a Buy at Needham
POSH Poshmark
$23.58 /

-1.77 (-6.98%)

10/04/21 Wedbush
Poshmark initiated with an Outperform at Wedbush
09/28/21 Berenberg
Poshmark initiated with a Buy at Berenberg
09/22/21 Needham
Needham starts Poshmark at Hold on sustained marketing spend margin pressure
TISI Team
$3.24 /

+0.11 (+3.51%)

TDUP ThredUP
$19.58 /

-1.01 (-4.91%)

RXDX Prometheus
$23.15 /

+0.79 (+3.53%)

RVLV Revolve Group
$62.34 /

-1.125 (-1.77%)

POSH Poshmark
$23.58 /

-1.77 (-6.98%)

NAPA Duckhorn Portfolio
$23.50 /

+0.26 (+1.12%)

MGPI MGP
$66.52 /

+0.37 (+0.56%)

LULU Lululemon
$392.49 /

-8.755 (-2.18%)

IVAC Intevac
$4.71 /

-0.04 (-0.84%)

CYBR CyberArk
$156.85 /

-2.66 (-1.67%)

CMTL Comtech
$25.52 /

-0.65 (-2.48%)

  • 29
    Jul
  • 26
    Mar
  • 18
    Mar
  • 12
    Mar
  • 14
    Jan
  • 18
    Nov
RVLV Revolve Group
$62.34 /

-1.125 (-1.77%)

NAPA Duckhorn Portfolio
$23.50 /

+0.26 (+1.12%)

LULU Lululemon
$392.49 /

-8.755 (-2.18%)

TDUP ThredUP
$19.58 /

-1.01 (-4.91%)

RVLV Revolve Group
$62.34 /

-1.125 (-1.77%)

POSH Poshmark
$23.58 /

-1.77 (-6.98%)

LULU Lululemon
$392.49 /

-8.755 (-2.18%)

CMTL Comtech
$25.52 /

-0.65 (-2.48%)

TDUP ThredUP
$19.58 /

-1.01 (-4.91%)

RXDX Prometheus
$23.15 /

+0.79 (+3.53%)

RVLV Revolve Group
$62.34 /

-1.125 (-1.77%)

POSH Poshmark
$23.58 /

-1.77 (-6.98%)

NAPA Duckhorn Portfolio
$23.50 /

+0.26 (+1.12%)

LULU Lululemon
$392.49 /

-8.755 (-2.18%)

Initiation
Cybin initiated with an Outperform rating, $7 target at Oppenheimer » 16:12
10/04/21
10/04
16:12
10/04/21
16:12
CYBN

Cybin

$2.12 /

-0.06 (-2.75%)

Oppenheimer analyst…

Oppenheimer analyst Francois Brisebois initiated coverage of Cybin with an Outperform rating and $7 price target. The company's most advanced product, CYB001, consists of sublingual psilocybin for patients with major depressive disorder, or MDD, noted Brisebois, who is "encouraged" that the company's delivery system offers potential for faster onset and improved bioavailability. Although CYB001 is further along, he views CYB003 for alcohol use disorder, or AUD, as "the main reason to own" the stock. CYB003's proprietary deuterated new chemical entity "could offer the most scalable psychedelic treatment option as a result of rapid onset, controlled delivery, shorter duration, and reduced dependence on the healthcare system," the analyst said.

ShowHide Related Items >><<
CYBN Cybin
$2.12 /

-0.06 (-2.75%)

CYBN Cybin
$2.12 /

-0.06 (-2.75%)

10/04/21 Oppenheimer
Cybin initiated with an Outperform at Oppenheimer
08/27/21 Canaccord
Cybin price target raised to $7 from $6 at Canaccord
08/26/21 Cantor Fitzgerald
Cybin initiated with an Overweight at Cantor Fitzgerald
Initiation
Cybin initiated with an Outperform at Oppenheimer » 16:06
10/04/21
10/04
16:06
10/04/21
16:06
CYBN

Cybin

$2.15 /

-0.03 (-1.38%)

Oppenheimer analyst…

Oppenheimer analyst Francois Brisebois initiated coverage of Cybin with an Outperform rating and $7 price target.

ShowHide Related Items >><<
CYBN Cybin
$2.15 /

-0.03 (-1.38%)

CYBN Cybin
$2.15 /

-0.03 (-1.38%)

08/27/21 Canaccord
Cybin price target raised to $7 from $6 at Canaccord
08/26/21 Cantor Fitzgerald
Cybin initiated with an Overweight at Cantor Fitzgerald
Syndicate
Cybin files C$125M mixed securities shelf  17:30
10/01/21
10/01
17:30
10/01/21
17:30
CYBN

Cybin

$2.18 /

+ (+0.00%)

 
ShowHide Related Items >><<
CYBN Cybin
$2.18 /

+ (+0.00%)

CYBN Cybin
$2.18 /

+ (+0.00%)

08/27/21 Canaccord
Cybin price target raised to $7 from $6 at Canaccord
08/26/21 Cantor Fitzgerald
Cybin initiated with an Overweight at Cantor Fitzgerald
Hot Stocks
Cybin retains services of ROK Consulting » 07:50
10/01/21
10/01
07:50
10/01/21
07:50
CYBN

Cybin

$2.18 /

-0.02 (-0.91%)

Cybin announces it has…

Cybin announces it has retained the services of ROK Consulting, an investor communications and public relations company, to "play a key role in assisting the company enhance its market awareness, communications strategy, and engagement with leading financial and institutional market participants," the company said. ROK has agreed to comply with all applicable securities laws and the policies of all applicable stock exchanges in providing services to the company. Under the terms of the ROK engagement, which is for an initial three-month period, ROK will be paid $500,000 per month and will be granted options to acquire up to 500,000 common shares in the capital of the Company exercisable at a price of CDN$2.78 per share until December 31, 2022.

ShowHide Related Items >><<
CYBN Cybin
$2.18 /

-0.02 (-0.91%)

CYBN Cybin
$2.18 /

-0.02 (-0.91%)

08/27/21 Canaccord
Cybin price target raised to $7 from $6 at Canaccord
08/26/21 Cantor Fitzgerald
Cybin initiated with an Overweight at Cantor Fitzgerald
Hot Stocks
Cybin announces new additions, promotions in management team » 07:10
10/01/21
10/01
07:10
10/01/21
07:10
CYBN

Cybin

$2.18 /

-0.02 (-0.91%)

Cybin announces: the…

Cybin announces: the addition of Dr. Amir Inamdar as its Chief Medical Officer for its European Operations, the addition of Dr. Geoff Varty as its new Head of Research & Development, the promotion of Lori Challenger to Chief Compliance, Ethics & Administrative Officer, and the promotion of Robert Mino to General Counsel.

ShowHide Related Items >><<
CYBN Cybin
$2.18 /

-0.02 (-0.91%)

CYBN Cybin
$2.18 /

-0.02 (-0.91%)

08/27/21 Canaccord
Cybin price target raised to $7 from $6 at Canaccord
08/26/21 Cantor Fitzgerald
Cybin initiated with an Overweight at Cantor Fitzgerald
Hot Stocks
Mindset identifies two additional 5-MeO-DMT-inspired lead candidates » 07:43
09/29/21
09/29
07:43
09/29/21
07:43
MSSTF

Mindset

/

+

Mindset Pharma announced…

Mindset Pharma announced that, in addition to its potential lead new chemical entity candidate, MSP-4018, the Company has identified two additional pipeline opportunities from its Family 4 compounds, MSP-4019 and MSP-4020. In preclinical studies, both compounds demonstrated strong efficacy and an improved safety profile in comparison to 5-MeO-DMT and parent compounds. Mindset's Family 4 compounds are DMT and 5-MeO-DMT-inspired novel drug candidates that offer a broad range of pharmacological diversity suitable for in-clinic settings. The Company has run a battery of specialized in-vitro and in-vivo tests on its patent-pending novel compounds to select the optimal psychedelic drug candidates for progressing towards human clinical trials.

ShowHide Related Items >><<
MSSTF Mindset
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.